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Behavioral/Systems/Cognitive
Activation of 4* nAChRs is Necessary and Sufficient for
Varenicline-Induced Reduction of Alcohol Consumption
Linzy M. Hendrickson,1,2 Rubing Zhao-Shea,1 Xueyan Pang,1 Paul D. Gardner,1,2 and Andrew R. Tapper1,2
1Brudnick Neuropsychiatric Research Institute, and 2Program In Neuroscience, University of Massachusetts Medical School, Worcester,
Massachusetts 01604
Recently, the smoking cessation therapeutic varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, has been shown to
reduce alcohol consumption. However, themechanism and nAChR subtype(s) involved are unknown. Here we demonstrate that vareni-
cline and alcohol exposure, either alone or in combination, selectively activates dopaminergic (DAergic) neurons within the posterior,
butnot the anterior, ventral tegmental area (VTA). Togain insight intowhichnAChRsubtypesmaybe involved in the response to alcohol,
we analyzed nAChR subunit gene expression in posterior VTA DAergic neurons. Ethanol-activated DAergic neurons expressed higher
levels of4,6, and3 subunit genes comparedwith nonactivated neurons. To examine the role of nicotinic receptors containing the4
subunit (4* nAChRs) in varenicline-induced reduction of alcohol consumption, we examined the effect of the drug in two complemen-
tary mouse models, a knock-out line that does not express the 4 subunit (4 KO) and another line that expresses 4* nAChRs
hypersensitive to agonist (Leu9Ala). While varenicline (0.1–0.3 mg/kg, i.p.) reduced 2% and 20% alcohol consumption in wild-type
(WT) mice, the drug did not significantly reduce consumption in 4 KO animals. Conversely, low doses of varenicline (0.0125–0.05
mg/kg, i.p.) that had little effect in WT mice dramatically reduced ethanol intake in Leu9Ala mice. Infusion of varenicline into the
posterior, but not the anterior VTA was sufficient to reduce alcohol consumption. Together, our data indicate that activation of 4*
nAChRs is necessary and sufficient for varenicline reduction of alcohol consumption.
Introduction
Complications from alcoholism are responsible for up to 1.8mil-
lion deaths per year making it the third largest cause of prevent-
able mortality in the world (World Health Organization, 2004).
Despite large costs to society, very few therapeutics that success-
fully aid in curbing alcohol consumption are available, highlight-
ing the need to identify newmolecular targets and treatments for
alcoholism. Recently, varenicline, a neuronal nicotinic acetylcho-
line receptor (nAChR) partial agonist, currently FDA approved as a
smoking cessation aid (Coe et al., 2005; Jorenby et al., 2006), was
shown to reduce drinking in alcohol preferring rats (Steensland et
al., 2007) and in a group of heavy-drinking smokers (McKee et al.,
2009), suggesting that nAChRsmay represent novel therapeutic tar-
gets for reducing alcohol consumption.
Ethanol is reinforcing, at least in part, by its propensity to
activate dopaminergic (DAergic) neurons within the ventral teg-
mental area (VTA) (Brodie and Appel, 1998; Brodie et al., 1999),
a key region of themesocorticolimbicDA system, resulting inDA
release in the nucleus accumbens (NAc), a phenomenon widely
associatedwith drug reinforcement (Soderpalm et al., 2009). Sev-
eral nAChR subunit genes are expressed throughout the meso-
corticolimbic DA system particularly in DAergic neurons of the
VTA. Neuronal nAChRs are ligand-gated, pentameric cation
channels normally activated by the endogenous neurotransmit-
ter, acetylcholine (ACh). Twelve mammalian genes encoding
neuronal nAChR subunits have been identified (2-10, 2-4)
which form either hetero- or homomeric receptors yielding a vast
array of nAChR subtypes with distinct pharmacological and bio-
physical properties (Albuquerque et al., 2009). Although ethanol is
not a direct agonist of nAChRs, alcohol increases ACh release into
the VTA (Ericson et al., 2003) and potentiates the response of high
affinity nAChR subtypes to ACh (Zuo et al., 2002).Mecamylamine,
a nonselective nAChR antagonist, either directly infused into the
VTA or delivered systemically, decreases ethanol-mediated DA re-
lease in the NAc (Blomqvist et al., 1997; Larsson et al., 2002)
and also decreases self-administration in rodents (Ericson et
al., 1998; Hendrickson et al., 2009). Thus, nAChR activation
modulates alcohol consumption and reinforcement.
While varenicline was designed as a selective 42* nAChR
partial agonist (Coe et al., 2005; Jorenby et al., 2006), it is also a
partial agonist at 32* and 6* nAChR subtypes, and a full
agonist at 34* and 7 nAChR subtypes (Mihalak et al., 2006).
Varenicline has also been shown to reduce alcohol consumption
in knock-out (KO) mice lacking expression of either 7 or 2*
nAChRs (Kamens et al., 2010). Thus, the nAChR subtype(s) that
varenicline targets to reduce alcohol consumption is unknown.
The goal of the present study was to localize and identify nAChR
subtypes expressed in the VTA that may be involved in the re-
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sponse to alcohol and to determinewhether they play a role in the
molecular mechanism by which varenicline reduces alcohol
consumption.
Materials andMethods
Animals. Adult (8- to 10-week-old), male C57BL/6J mice bred in house
were used for immunohistochemistry, gene expression, and brain infu-
sion experiments (n  46). For consumption experiments, adult, male
4 knock-out (4 KO) mice and their wild type (WT) litter mates (n
45), as well as heterozygous Leu9Ala knock-in mice and their WT litter
mates (n  42), all bred on site, were used. The genetic engineering of
both 4 KO and Leu9Ala mouse lines have been described previously
(Ross et al., 2000; Tapper et al., 2004). Both lines have been back-crossed
to a C57BL/6J background for at least nine generations. C57BL/6J mice
were group housed four mice/cage and given food and water ad libitum.
For consumption experiments, mice were individually housed on a re-
versed 12 h light/dark cycle (lights on 10PM, off 10:00 A.M.) with ad
libitum access to food andwater (except during experiments as described
below). All experiments were conducted in accordance with the guide-
lines for care and use of laboratory animals provided by the National
Research Council (National Research Council, 1996), as well as with an
approved animal protocol from the Institutional Animal Care and Use
Committee of the University of Massachusetts Medical School.
Drugs and drinking solutions. Ethanol drinking solutions were pre-
pared from 190 proof absolute anhydrous ethanol (Pharmco-Aaper) di-
luted to 2% or 20% ethanol (v/v) using tap water. Sucrose was dissolved
in tap water to make a 10% (w/v) concentration. Varenicline tartrate, a
gift from Pfizer, and ethanol were dissolved in 0.9% saline and adminis-
tered via intraperitoneal injection at the indicated doses. For infusion of
drug into the brain, varenicline was dissolved in artificial CSF (aCSF
containing, in mM: 126 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 1.25 NaH2PO4,
26 NaHCO3, 25 D-glucose). For immunohistochemistry and behavioral
experiments, varenicline doses were chosen based on previous studies of
varenicline effects on nicotine self-administration and DA turnover in
addition to predicted therapeutic concentrations achieved in smokers’
brains (O’Connor et al., 2010; Rollema et al., 2010). Varenicline concen-
trations are reported as free base.
Immunohistochemistry. Adult (8- to 10-week-old), male, C57BL/6J
mice were injected intraperitoneally with saline for 3 d before the start of
the experiment to habituate them to handling and to reduce c-Fos acti-
vation due to stress. Four groups of three mice were used in each of the
following conditions: an intraperitoneal injection of saline followed by
an intraperitoneal injection of saline, an intraperitoneal injection of sa-
line followed by a 2.0 g/kg ethanol injection, an intraperitoneal injection
of 0.3 mg/kg varenicline followed by a saline injection, and 0.3 mg/kg
varenicline i.p. injection followed by a 2.0 g/kg ethanol injection. The
time between the first and second injections was 15 min. Ninety minutes
after the second injection, all mice were deeply anesthetized with sodium
pentobarbital (200mg/kg, i.p.) and perfused transcardially with 10ml of
0.1 M PBS followed by 10 ml of 4% paraformaldehyde in 0.1 M sodium
phosphate buffer, pH7.4. Brainswere removed andpostfixed for 2 hwith
the same fixative and cryoprotected in sodiumphosphate buffer contain-
ing 30% sucrose until brains sank. VTA serial coronal sections (20 m)
were cut on a microtome (Leica Microsystems Inc.) and collected into a
24-well tissue culture plate containing 1 PBS. Slices containing VTA
were collected between 2.8 mm and 4.04 mm from bregma. After
rinsing sections in PBS twice for 5 min, they were treated with 0.2%
Triton X-100 PBS (PBST) for 5 min followed by incubation in 2% BSA/
PBS for 30min. Sections were washed with PBS once and then incubated
in a mixture of primary antibodies for tyrosine hydroxylase (TH, mono-
clonal, 1:250 dilution, Santa Cruz Biotechnology) and c-Fos (polyclonal,
1:400 dilution, Santa Cruz Biotechnology) in 2% BSA/PBS overnight at
4°C. The sections were then washed with PBS three times for 5 min
followed by incubation in secondary fluorescent labeled antibodies (goat
anti-rabbit Alexa Fluor 488 and goat anti-mouse Alexa Fluor 594, 1:300
dilutions, Invitrogen) at room temperature in the dark for 30 min. After
washing with PBS 5 times for 5 min/wash, sections were mounted on
slides using Vectashield Mounting Medium (Vector Laboratories). The
number of positive neurons was counted under a fluorescence micro-
scope (Carl Zeiss MicroImaging Inc.) at a magnification of 400. The
intensity of fluorescence was quantified using a computer-associated im-
age analyzer (Axiovision Rel. 4.6). Neurons were counted as signal-
positive if intensities were at least 2 times higher than that of the average
value of background (sections stained without primary antibodies). Ex-
perimenters were blind to drug treatment.
Laser capturemicrodissection.Adult,maleC57BL/6Jmicewere injected
intraperitoneally with saline for 3 d before the start of the experiment to
habituate them to handling and to reduce c-Fos activation due to stress.
On the experiment day, mice were injected intraperitoneally with 2.0
g/kg ethanol and decapitated 90min later. The brain was removed, snap-
frozen in dry ice-cooled 2-methylbutane (60°C) and stored at80°C.
Coronal serial sections (10 m) of the VTA were cut using a cryostat
(Leica Microsystems Inc.) and mounted on precleaned glass slides
(Fisher Scientific). The sections were immediately placed in a slide box
on dry ice until completion of sectioning followed by storage at80°C.
A quick immunofluorescence double-staining protocol for TH and
c-Fos was used to identify TH and c-Fos-immunopositive neurons. First,
frozen sections were allowed to thaw for 30 s then immediately fixed in
cold acetone for 4min. Slides were then washed in PBS, incubated with a
mixture of primary antibodies for mouse anti-TH and rabbit anti-c-Fos
(Santa Cruz Biotechnology, 1:50 dilutions) for 10 min, washed in PBS
once followed by incubation in secondary fluorescent-labeled antibodies
(Invitrogen, a mixture of goat anti-mouse Alex Fluor 594 and goat anti-
rabbit Alex Fluor 488, 1:100 dilution) for 10min. The slides were washed
in PBS once, then subsequently dehydrated in a graded ethanol series (for
30 s each in 70% ethanol, 95% ethanol, 100% ethanol, and once for 5min
in xylene). Slides were allowed to dry for 5 min. All antibodies were
diluted in DEPC-treated PBS containing 2% BSA and 0.2% Triton
X-100. All ethanol solutions and xylene were prepared fresh to preserve
RNA integrity.
The Veritas Microdissection SystemModel 704 (Arcturus Bioscience)
was used for laser capture microdissection (LCM). Approximately 800–
1400 TH-immunopositive neurons (including c-Fos-immunopositive
and c-Fos-immunonegative) were cut from the VTA in each animal. Five
to seven different mice were used per treatment. Neurons were captured
onCapSureMacro LCMcaps (Arcturus Bioscience) formRNA isolation.
Real-time PCR. Total RNA was extracted from individual replicate
samples using a Micro Scale RNA Isolation Kit (Ambion). RNA samples
extracted from DAergic neurons were reverse-transcribed into cDNA
using TaqMan Gene Expression Cells-to-CT Kit (Ambion). PCRs were
set up in 10 l reaction volumes using TaqMan Gene Expression Assays
(Applied Biosystems). GAPDH was used as an internal control gene to
normalize gene expression levels. PCR was performed using an ABI
PRISM7500 SequenceDetection System (Applied Biosystems). Negative
controls with no reverse transcriptase were performed for all Taqman
Assays. All reactions were performed in triplicate. Relative amplicon
quantification was calculated as the difference between Ct values of
GAPDH and that of the gene of interest. Relative gene expression differ-
ences between c-Fos-immunopositive neurons and c-Fos-immuno-
negative neurons were calculated using the 2Ct method.
Drinking in the dark. Ethanol consumption was measured using a
Drinking in the Dark (DID) procedure similar to that previously de-
scribed (Hendrickson et al., 2009). Animals were singly housed in exper-
imental chambers for 1 week before the beginning of the DID sessions.
The mice received a 15 ml graduated water bottle fitted with a one-hole
rubber stopper with a stainless steel double-ball-bearing sipper tube
which was sealed with Parafilm to prevent leakage. For the first three
nights, 2 h after the lights were off, mice were injected intraperitoneally
with saline immediately before their water bottle was replaced with the
ethanol bottle (2% or 20%), and allowed to drink for 2 h. This procedure
was used to acclimatize the mice to the experimental conditions and
allow them to reach a baseline of ethanol intake before drug administra-
tion. On the fourth night, the mice received their first dose of drug just
before placement of the ethanol bottle. The amount of ethanol consumed
was recorded after each 2 h session and converted to g/kg per each ani-
mal’s ethanol consumption and body weight. The mice were given 2 d of
rest (no injections or ethanol) and then began the saline injection/etha-
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nol consumption assay for 2–3 d or until a stable ethanol intake was
reached. Once the baseline returned, a second, higher dose of drug was
administered before the ethanol bottle being placed in the cage. In this
design, all mice in one group drink a single concentration of ethanol
throughout the experiment, but receive two doses of drug, 4–5 d apart,
with the lower concentration of drug first. The baseline value immedi-
ately before the first drug exposure is shown in all figures. There was no
significant difference in baseline ethanol intake between doses in any of
the experiments (data not shown). For control experiments, mice re-
ceived 10% sucrose for 2 h instead of ethanol.
Cannula surgeries.C57BL/6J mice were anesthetized with a mixture of
ketamine (100 mg/kg) and xylazine (10 mg/kg) (VEDCO). The surgical
area was shaved and disinfected. Mice were placed in a stereotaxic frame
(Stoelting Co.) with mouse adaptor and a small incision was cut in the
scalp to expose the skull. Using bregma and lambda as landmarks, the
skull was leveled in the coronal and sagittal planes. For cannula place-
ment, holes were drilled in the skull at the anteroposterior (AP, in refer-
ence to bregma) and mediolateral (ML) coordinates that correspond to
either the anterior VTA (2.6 mmAP, 0.5 mmML) or posterior VTA
(3.4 mm AP,  0.5 mm ML) based on the work of Paxinos and
Franklin (2000). Stainless steel unilateral guide cannulas (4.0 mm
dorsal ventral, Plastics One) with dummy cannulas in place, were
inserted into the brain and secured to the skull with Cerebond (Plas-
tics One). Mice were allowed to recover for at least 3 d before behav-
ioral testing.
Intra-VTA infusions and DID. Two hours after the lights were turned
off, mice were anesthetized with 2% isoflurane via a nose cone adaptor at
a flow rate of 800 ml/L. Once anesthetized, an infusion cannula designed
to reach4.5 mm below the skull was inserted
into the guide cannula and vehicle, 10 pmol,
100 pmol, or 1000 pmol of varenicline was in-
fused at a rate of 1 l/min for 45 s and a total
volume of 0.75 l. Immediately after infusion,
mice were placed back into their home cages
andmonitored until awake,45 s. During this
time, the home cage water bottle was removed
and replaced with a bottle containing 20% eth-
anol, which was left in place for 2 h as previ-
ously described for the DID experiments.
Before the start of each experiment, mice were
infusedwith vehicle daily until a stable baseline
of ethanol intake was reached. After comple-
tion of behavioral experiments, mice were
culled and brains were removed and frozen on
dry ice. Coronal sections (20 m) were cut
with a cryostat (Leica Microsystems Inc.). Sec-
tions were mounted and stained with neutral
red (Sigma) to visualize cannula placement. A
total of 6mice were excluded from analysis due
to incorrect cannula placement.
Data analysis.Datawere analyzed using two-
way ANOVA with drug treatment and either
genotype or brain region as variables as indi-
cated followed by Bonferroni post hoc tests.
Data were analyzed using GraphPad software.
Paired t tests were used to analyze fold expres-
sion of qRT-PCRdata. Results were considered
significant at p 0.05. All data are expressed as
means SEM.
Results
Varenicline and alcohol activate
DAergic neurons within posterior VTA
Recent evidence suggests that the VTA is
not a homogeneous brain structure but is
divided into distinct subregions (Ikemoto,
2007; Shabat-Simon et al., 2008). Thus,
using c-Fos expression as amarker of neu-
ronal activation and TH as a marker of
DAergic neurons of the VTA, we examined the activating effects
of varenicline and ethanol alone and in combination throughout
the VTA. TheVTAwas divided into two distinct regions, anterior
and posterior, using known neuroanatomical landmarks and ste-
reotaxic coordinates based on the work of Paxinos and Franklin
(2000) and previous publications (Shabat-Simon et al., 2008).
C57BL/6J mice were injected intraperitoneally with drug(s) and
their brains were examined for c-Fos expression within TH-
immunopositive neurons 90 min later. Overall, there was a sig-
nificant main effect of brain region (F(1,20)  166.5, p  0.001),
treatment (F(3,20)  49.21, p  0.001), and a significant brain
region treatment interaction (F(3,20) 28.25, p 0.001). Mice
treated with 0.3 mg/kg varenicline followed by a saline injection
exhibited an increase in the number of TH-, c-Fos-immuno-
positive neurons,whichwere restricted to the posteriorVTA (Fig.
1A,B). Mice injected intraperitoneally with saline, followed by 2
g/kg ethanol, also displayed a dramatic increase in the number of
TH-, c-Fos-immunopositive neurons within the posterior but
not anterior VTA (Fig. 1A,B). Finally, mice injected intraperito-
neally with 0.3 mg/kg varenicline followed by 2.0 g/kg ethanol
also exhibited a significant increase in the number of TH-, c-Fos-
immunopositive neurons restricted to the posterior VTA (Fig.
1A,B). Bonferroni post-tests revealed that each treatment con-
dition was significantly different from control injections (sa-
line/saline) within the posterior VTA (Fig. 1B, p  0.001).
Figure1. Varenicline activatesDAergic neuronswithin theposterior VTA.A, Representative images of coronal sections from the
anterior (left) and posterior (right) VTA. Sections were isolated from C57BL/6J mice injected with saline, 0.3 mg/kg varenicline, 2
g/kg ethanol, or bothdrugs. Sectionswere immunolabeled todetect THexpression (red, left columns) and c-Fos expression (green,
middle columns). Merged images are represented in the right column. B, Quantification of the number of TH-, c-Fos-
immunopositive [TH (	), c-Fos (	)] neuronswithin each region of the VTA after each drug treatment (34–51 slices analyzed per
region, n 3 mice/treatment). ***p 0.001.
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There were no significant effects of treatment on the number
of TH-, c-Fos-immunopositive neurons within the anterior
VTA when compared with saline injection. These results are
consistent with the finding that the VTA can indeed be divided
into distinct regions and that ethanol and varenicline predom-
inantly activate DAergic neurons within the posterior VTA.
Differential expression of nAChR subunits in
alcohol-activated posterior VTA neurons
To gain insight into potential nicotinic receptor subunits that
may be involved in alcohol activation of posterior VTA DAergic
neurons, we challenged C57BL/6J mice with 2.0 g/kg ethanol and
used LCM and qRT-PCR to analyze nicotinic receptor gene
expression in activated, TH-, c-Fos-immunopositive neurons
compared with nonactivated, TH-immunopositive, c-Fos-
immunonegative neurons. mRNA from the two groups of neu-
rons (Fig. 2A) only within the posterior VTA was isolated and
reverse transcribed. Neuronal nAChR subunit gene expression
was then analyzed using qRT-PCR. In TH-, c-Fos-immuno-
positive neurons, the order of expression for nicotinic receptor
subunit genes, fromhighest to lowest expression, was:4
6

3 
 2 
 7 
 3 
 5. For TH-immunopositive, c-Fos-
immunonegative neurons, the order of expression was: 4 

3
 2
 6
 7
 3
 5 (Table 1). A paired t test showed
significantly higher levels of expression of the 4 (t 2.24, df
4, p 0.05),6 (t 4.06, df 3, p 0.05), and3 (t 4.28, df
4, p 0.01) nAChR subunit genes as well as c-Fos (t 2.69, df 3,
p 0.05) in the c-Fos-immunopositive neurons compared with
c-Fos-immunonegative neurons (Fig. 2B, Table 1). These results
indicate specific nAChR subtypes (463*) may be impor-
tant for modulating alcohol activation of posterior VTA
DAergic neurons.
Role of4* nAChRs in varenicline-induced reduction of
alcohol consumption
Because (1) the specific role of 4* nAChR in alcohol consump-
tion has not been described and (2) 4 gene expression was
higher in DAergic neurons activated by ethanol within posterior
VTA, we tested the hypothesis that varenicline may reduce alco-
hol consumption via these receptors. First, we examined the ef-
fects of 0.1mg/kg and 0.3mg/kg varenicline on 2%alcohol intake
in mice that do not express 4* nAChRs (4 KO), and their WT
litter mates (Fig. 3A). There was a significant main effect of treat-
ment (F(2,45) 8.0, p 0.001) but not genotype and there was no
significant interaction between these two factors. Both doses of
varenicline significantly decreased 2% ethanol consumption in
WTmice comparedwith saline ( p 0.01 for both doses), but did
not reduce consumption in 4 KO mice (Fig. 3A). This experi-
ment was repeated in a separate group of animals with the same
doses of varenicline, but using a higher concentration of alcohol,
20%. Two-way ANOVA revealed a significant main effect of
treatment (F(2,64)  5.31, p  0.01), genotype (F(1,64)  12.11,
p  0.001), and a significant treatment  genotype interaction
(F(2,64)  3.19, p  0.05). Whereas WT and 4 KO mice con-
sumed similar baseline quantities of 2% alcohol, baseline 20%
alcohol consumption after saline injection was significantly
less in 4 KO mice compared with WT ( p  0.01, Fig. 3B).
Varenicline significantly decreased 20% ethanol consumption
in WT animals (Fig. 3B) and post hoc tests indicated that alco-
hol consumption after each varenicline dose was significantly
lower compared with consumption after saline injection ( p
0.01 for both doses). In 4 KO mice, alcohol consumption
after either varenicline dose was not significantly different
compared with consumption after saline. Thus, these data
Figure2. Differential nAChR subunit gene expression in alcohol-activated versus nonactivatedDAergic neurons.A, Immunofluorescence imageof a coronalmidbrain slice fromaC57BL/6Jmouse
challenged with 2.0 g/kg ethanol. Sections were immunolabeled to detect TH (red) expression to visualize DAergic neurons and c-Fos (green) expression to identify neurons activated by ethanol.
Arrows point to two different cells, one, a TH-immunopositive c-Fos-immunonegative neuron [TH (	), c-Fos ()] and the other a TH-, c-Fos-immunopositive neuron [TH (	), c-Fos (	)].B, Fold
change of nAChR subunit gene expression, as measured by qRT-PCR, in TH-, c-Fos-immunopositive (left) neurons compared with TH-immunopositive, c-Fos-immunonegative neurons (right).
Neurons were captured via LCM. TH-, c-Fos-immunopositive neurons n 2298 and TH-immunopositive, c-Fos-immunonegative n 3645. *p 0.05, **p 0.01, paired t test.
Table 1. Quantitative gene expression of nAChR subunit genes in pVTA DAergic neurons either activated or not activated by 2.0 g/kg ethanol [TH (), c-Fos () or TH (),
c-Fos (), respectively]
nAChR subunit 3 4* 5 6* 7 2 3** c-Fos**
TH (	), c-Fos (	) 8.12 0.42 2.51 0.33 9.54 0.46 4.42 0.44 7.05 0.41 4.89 0.42 4.84 0.42 4.51 0.68
TH (	), c-Fos () 7.97 0.61 3.70 0.31 9.66 0.55 5.71 0.30 7.83 0.38 5.47 0.37 5.43 0.34 7.38 0.30
Comparison of nAChR subunit gene expression (Ct ) of c-Fos-immunopositive and c-Fos-immunonegative DAergic neurons in pVTA after an acute ethanol (2 g/kg) injection. Values represent the negative change in threshold cycle
(Ct ) compared with GAPDH. *p 0.05, **p 0.01, paired t test.
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suggest that expression of 4* nAChRs is necessary for
varenicline-induced reduction of ethanol consumption.
To determine whether activation of 4* nAChRs by vareni-
cline was sufficient to decrease ethanol intake, we analyzed the
effect of low doses of drug on alcohol consumption in mice ex-
pressing a single point mutation, Leu9Ala, that renders 4*
nAChRs hypersensitive to agonist (Tapper et al., 2004). Leu9Ala
and WT litter mate mice were challenged with intraperitoneal
injections of 0.0125 mg/kg and 0.05 mg/kg varenicline before
receiving a 2% ethanol bottle. There was a significant main effect
of treatment (F(2,55)  6.86, p  0.01) and genotype (F(1,55) 
6.14, p  0.05) and a significant treatment  genotype interac-
tion (F(2,55)  3.74, p  0.05). Surprisingly, both low doses of
varenicline significantly decreased 2% ethanol intake in Leu9Ala
(0.0125 mg/kg and 0.05 mg/kg compared with saline, p  0.01
and p 0.001, respectively) but notWTmice (Fig. 3C).However,
higher doses (0.1 mg/kg and 0.3 mg/kg) of varenicline did signif-
icantly reduce consumption in WT mice (Fig. 3C, p 0.05, and
p  0.01 comparing 0.1 mg/kg and 0.3 mg/kg varenicline to
saline, respectively). Similar results were obtained when this
experiment was repeated and the concentration of alcohol was in-
creased to 20%. There was a main effect of treatment (F(2,40) 
6.73, p 0.01) and genotype (F(1,40) 22.65) but no significant
interaction. Varenicline significantly decreased ethanol con-
sumption in Leu9Ala but not WT mice when challenged with
low doses of the drug, and each dose of
varenicline was significantly different
compared with a saline injection (Fig. 3D,
p  0.01 for both doses). Together, these
data suggest that selective activation of
4* nAChRs by varenicline is sufficient
for reduction of alcohol consumption.
Importantly, varenicline did not sig-
nificantly reduce 10% sucrose consump-
tion in any of the genotypes, indicating
that the effect of varenicline was specific
for alcohol intake (Fig. 3E).
Varenicline infusion into the anterior
and posterior VTA
To determine whether varenicline reduc-
tion of alcohol consumption was medi-
ated by drug action in the posterior VTA,
we selectively infused the drug into either
the anterior or posteriorVTAofC57BL/6J
mice andmeasured alcohol consumption.
Guide cannulas were implanted into ei-
ther brain region (see methods) and vehi-
cle, 10, 100, or 1000 pmol of varenicline
was infused into the VTA before presen-
tation of a 20% alcohol bottle. Figure 4, A
and B, depicts the location of the guide
cannula within each mouse brain from
the two groups of animals. Two-way
ANOVA revealed a significant main effect
of treatment (F(3,47) 3.13, p 0.05) and
brain region (F(1,45) 4.88, p 0.05) and
a significant treatment brain region in-
teraction (F(3,47) 4.39, p 0.01). When
infused into the anterior VTA, varenicline
did not significantly reduce alcohol con-
sumption compared with vehicle infusion
(Fig. 4C). However, 10, 100, and 1000
pmol of varenicline, when infused into the posterior VTA, signif-
icantly reduced alcohol consumption (Fig. 4C, p 0.01, p 0.05,
and p  0.01 respectively). These data indicate that infusion of
varenicline into the posterior VTA is sufficient to reduce alcohol
consumption.
Discussion
Because alcohol is one of the most commonly abused psychoac-
tive drugs in the world resulting in significant health conse-
quences, it is critical to identify novel therapies and molecular
targets to treat alcoholism. The nAChR partial agonist, vareni-
cline, is an FDA approved smoking cessation aid that may hold
promise as a treatment for alcoholism (Coe et al., 2005; Gonzales
et al., 2006). For example, varenicline reduces alcohol consump-
tion and seeking in rats (Steensland et al., 2007) and also signifi-
cantly reduces consumption in heavy drinking smokers (McKee
et al., 2009). Althoughmuch is known about howvareniclinemay
reduce nicotine dependence, much less is known regarding the
brain regions and nAChR subtypes that varenicline may target to
reduce alcohol consumption.
Varenicline-induced activation of the posterior VTA reduces
alcohol consumption
Our data indicate that varenicline and ethanol interact in the
VTA. Indeed, much emphasis has been placed on the VTA be-
Figure 3. Alcohol intake after varenicline treatment in4 KO, Leu9Ala andWTmice.A, Ethanol intake (2%) inWT and4 KO
mice after saline or varenicline treatment (n 8–9/genotype). B, Ethanol intake (20%) in WT and 4 KO mice after saline or
varenicline treatment (n 10–12/genotype). C, Effect of saline and varenicline on 2% ethanol intake in WT and Leu9Ala (n
10–11/genotype). D, Effect of saline and varenicline on 20% ethanol intake in Leu9Ala and WT mice (n 6–9/genotype). E,
Effect of varenicline treatment on 10% sucrose intake (n 5–11/genotype) inWT,4 KO, and Leu9Alamice. *p 0.05, **p
0.01, ***p 0.001, ^p 0.01 (4 KO compared with WT after saline injection).
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cause of its central importance in the me-
socorticolimbic reward pathway (Funk et
al., 2006). Alcohol activates DAergic neu-
rons within this region, ultimately in-
creasing DA release in the NAc and driving
dependence (Pidoplichko et al., 1997;
Brodie and Appel, 1998; Brodie et al.,
1999; Mansvelder et al., 2002). Mounting
evidence indicates that the VTA is not a
homogeneous brain region; rather it can
be anatomically and functionally divided
into at least two brain regions, the ante-
rior and posterior VTA (Ikemoto, 2007;
Shabat-Simon et al., 2008). Although both
regions of the VTA contain predomi-
nantly two subtypes of neurons, DAergic
projection neurons and local GABAergic
interneurons, studies have shown that
neurons within the anterior and posterior
VTA project to distinct regions of stria-
tum and also may respond differently
to drugs of abuse (Zangen et al., 2006;
Ikemoto, 2007; Shabat-Simon et al., 2008).
The predominant VTA subregion that is
critical for alcohol’s action in the VTA is
unclear. Previous studies indicate that
the anterior VTA is an important mod-
ulator of alcohol intake (Ericson et al.,
2008; Moore and Boehm, 2009) while
others find a role for the posterior VTA
(Linsenbardt and Boehm, 2009). Addi-
tionally, local infusion of ethanol into the anterior VTA does not
increase NAc DA output (Ericson et al., 2003; Lo¨f et al., 2007a)
while local infusion of ethanol to the posterior VTA is sufficient
for increased DA release in the NAc (Ding et al., 2009). Our data
are in line with previous work highlighting the importance of the
posterior VTA in alcohol-mediated activation of DAergic neu-
rons. Injection of 2.0 g/kg alcohol, a dose that conditions a place
preference in C57BL/6J mice (i.e., a rewarding dose) activated
DAergic neurons predominantly in the posterior VTA. Vareni-
cline also activatedDAergic neurons selectively in this region and
infusion of varenicline directly into the posterior, but not ante-
rior, VTA reduced alcohol consumption, suggesting that the pos-
terior VTA, specifically, could be a neuroanatomical substrate
where both drugs interact. Thus, our data support previous stud-
ies indicating that rats will self-administer nicotine or ethanol
directly into the posterior, but not anterior, VTA (Rodd-
Henricks et al., 2000; Rodd et al., 2004; Ikemoto et al., 2006).
Activation of DAergic neurons by alcohol at least partially
mediates the rewarding properties of the drug. Interestingly,
varenicline also activates these neurons and this reduces alcohol
consumption. Although the precise mechanism of this effect is
unknown, one possibility is that activation ofDAergic neurons by
varenicline precludes further activation by alcohol. At themolec-
ular level, vareniclinemay serve to occupy or desensitize nAChRs
necessary for alcohol activation of DAergic neurons, thereby re-
ducing DA release in the NAc and decreasing consumption. Sup-
porting this idea, varenicline has been shown to reduce alcohol
stimulated NAc DA release in rats (Ericson et al., 2009). This
would also be consistent with the mechanism by which vareni-
cline is thought to reduce nicotine reinforcement (Rollema et al.,
2007).
The role of nAChRs in alcohol consumption
Reduction of alcohol consumption by varenicline indicates that
nAChRs may play a critical role in the reinforcing properties of
ethanol. Several studies have used various nicotinic agonists and
antagonists to implicate nAChR activation as potentially impor-
tant for alcohol consumption. The nonspecific nAChR antago-
nist, mecamylamine, either delivered systemically or selectively
into the VTA, reduces alcohol intake and blocks alcohol-
mediated DA release in NAc (Blomqvist et al., 1993, 1996, 1997;
Hendrickson et al., 2009). However, specific nicotinic receptor
subtypes involved in alcohol consumption are unclear. Previous
studies have demonstrated that the selective 42* nAChR com-
petitive antagonist, DHE, fails to modulate alcohol consump-
tion suggesting that this subtype may not be involved in the
response to alcohol (Leˆ et al., 2000;Hendrickson et al., 2009). The
7 selective antagonist, methyllycaconitine, also does not reduce
alcohol intake (Hendrickson et al., 2009). To gain insight into
nAChR subtypes that may influence alcohol consumption, and
be targeted by varenicline, we compared nAChR subunit gene
expression between posterior VTA DAergic neurons that were
activated by alcohol and posterior VTA DAergic neurons not acti-
vatedbyalcohol.WefoundthatDAergicneurons thatwereactivated
by alcohol express higher levels of 4, 6, and 3 nAChR subunit
transcripts. Although this difference in mRNA expression does
not necessarily translate into protein and/or assembled receptor
expression, these data suggest that 463* nAChRs may be
involved in alcohol consumption. Our results are consistent with
previous studies indicating that the 6/3* nAChR selective an-
tagonist -conotoxin MII, when infused into the VTA, can re-
duce alcohol consumption and block alcohol-mediated DA
release in NAc (Larsson et al., 2004; Jerlhag et al., 2006; Lo¨f et al.,
2007b). Importantly, a significant portion of63* nAChRs also
Figure 4. Alcohol intake after varenicline infusion into anterior or posterior VTA. A, Left, representative neutral red stained
coronal brain slice fromamousewith a guide cannula placed just dorsal to the anterior VTA (dotted box). Right, schematic diagram
of anterior VTA3.08 mm from bregma (adapted from Paxinos and Franklin, 2000). X’s represent guide cannula placements
within the anterior VTA. B, Left, representative neutral red stained coronal brain slice from a mouse with a guide cannula placed
just dorsal to the posterior VTA (dotted box). Right, schematic diagram of posterior VTA at bregma3.52. X’s represent guide
cannula placements within the posterior VTA. C, Ethanol intake (20%) after infusion of aCSF, 10 pmol, 100 pmol, or 1000 pmol of
varenicline in either the anterior or posterior VTA (n 9–10/brain region). *p 0.05, **p 0.01.
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contain the 4 subunit and these receptors represent one of the
highest affinity nAChRs identified in the brain thus far (Salminen
et al., 2004, 2007).
Activation of4* nAChRs are critical for varenicline-induced
reduction of alcohol consumption
The role of 4* nAChRs in varenicline reduction of alcohol con-
sumption has not been examined previously. We used two com-
plementary genetic nAChR mouse models, one lacking the gene
encoding the 4 subunit, CHRNA4 (4 KO) (Ross et al., 2000)
and another that has a single point mutation, Leu9Ala, within
the endogenous CHRNA4 exon 5 resulting in 4* nAChRs that
are hypersensitive to agonist (Leu9Ala) (Tapper et al., 2004;
Fonck et al., 2005). Varenicline reduced consumption of both a
low and high dose of alcohol inWTmice but did not significantly
reduce consumption in4 KOmice indicating that expression of
4* nAChRs is necessary for the effects of the drug. In contrast to
the effects of varenicline in the KO animals, low doses of vareni-
cline that had little effect on consumption in WT mice dramati-
cally reduced ethanol intake in Leu9Ala mice suggesting that
activation of 4* nAChRs is also sufficient for varenicline effects
on alcohol consumption. Importantly, varenicline did not reduce
sucrose intake indicating that the effects of the drug were specific
for alcohol consumption and did not dampen general reward
signaling. Because varenicline may also target 7 as well as other
nAChR subtypes in addition to 42* nAChRs, the mechanism
by which varenicline reduces alcohol consumption is an open
question (Mihalak et al., 2006; Papke et al., 2010). A recent study
demonstrated that varenicline reduced ethanol consumption in
mice lacking either 7 or 2* nAChRs similar toWT (Kamens et
al., 2010), indicating that expression of these receptors is not
necessary for varenicline’s effects. As discussed above, our data
suggest that 463* nAChRs mediate varenicline’s effects on
alcohol consumption, although it is expected that this subtype
should also contain the 2 subunit (Grady et al., 2007). Thus,
varenicline reduction of ethanol intake in2 KOmicemay occur
because of compensatory mechanisms in nAChR expression or
subunit composition. Alternatively, we cannot rule out the pos-
sibility that higher doses of varenicline than used in our study
may reduce alcohol consumption by a non-4* nAChR-
dependent mechanism. However, we expect that the doses we
used would result in concentrations of varenicline more selective
for high affinity nAChRs. For example, 0.1 mg/kg varenicline is
predicted to yield a brain concentration of 38 nM (Rollema et al.,
2009). This concentration is predicted to be within the range
experienced by smokers taking therapeutic doses of varenicline
(Rollema et al., 2010). Similar doses also reduce nicotine self-
administration in rats without impacting food reinforcement
unlike higher doses (O’Connor et al., 2010). In addition, this
range of varenicline dose also increases DA turnover in rat
NAc (Rollema et al., 2010) consistent with our data illustrating
that 0.3 mg/kg varenicline activates DAergic neurons.
Together, our results demonstrate that ethanol and vareni-
cline selectively activate DAergic neurons within the posterior
VTA and that activation of 4* nAChRs is necessary and suffi-
cient for varenicline-induced reduction of ethanol consumption.
Our data combined with recent clinical studies indicate that
varenicline could potentially be a therapeutic candidate for the
treatment of alcoholism.
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